Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2022 19:00 ET | Source: Allied Market Research

Flow Diverters Market to Hit $1.04 Billion, with CAGR of 15.3% by 2031: Allied Market Research

Portland, OR, Nov. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Flow Diverters Market generated $251.50 million in 2021, and is...
September 04, 2018 07:30 ET | Source: InspireMD, Inc.

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
June 29, 2018 10:24 ET | Source: InspireMD, Inc.

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
June 11, 2018 09:53 ET | Source: InspireMD, Inc.

InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress

Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
May 30, 2018 07:31 ET | Source: InspireMD, Inc.

InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS

Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...
May 07, 2018 16:05 ET | Source: InspireMD, Inc.

InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018

Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
May 01, 2018 07:00 ET | Source: InspireMD, Inc.

InspireMD Schedules First Quarter 2018 Earnings Conference Call

TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
April 30, 2018 07:34 ET | Source: InspireMD, Inc.

InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS™ and MGuard™ Prime Products in Vietnam

TEL AVIV, ISRAEL, April 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
April 03, 2018 10:28 ET | Source: InspireMD, Inc.

InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million

TEL AVIV, Israel, April 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
March 05, 2018 08:07 ET | Source: InspireMD, Inc.

InspireMD Announces First Patient Treated with CGuard™ EPS in India

Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard™ EPS TEL AVIV, ISRAEL, March 05, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader...

Next Page keyboard_arrow_right